Inhibikase Therapeutics IKT
NASDAQ IKT
$1.66 -0.05 (-2.92%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inhibikase Therapeutics (IKT) Long-Term Debt Repayments (2021 - 2022)

Updated

Inhibikase Therapeutics (IKT) reported Long-Term Debt Repayments of $248,911 for FY2022, up 485.2% from $42,534 in FY2021.

Analysis

Inhibikase Therapeutics (IKT) Long-Term Debt Repayments (2021 - 2022) Analysis & Trends

  • According to Business Quant data, Long-Term Debt Repayments came in at $42,534 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 1.00 Mn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 2.00 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 2.46 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 17.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Inhibikase Therapeutics 288.92 Mn -296.56 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 248,911.00
Jun 30, 2021 -367,128.00
Mar 31, 2021 409,662.00
API Access

Inhibikase Therapeutics Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=IKT&period=max&api_key=YOUR_API_KEY